Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy

Metabolism: Clinical and Experimental

Volumn 60, Issue 8, 2011, Pages 1064-1069

  Chang, Yu Hung ^a   Lin, Kun Der ^a,b   He, Sin Ru ^b   Hsieh, Ming Chia ^a   Hsiao, Jeng Yueh ^a   Shin, Shyi Jang ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ALBUMINURIA; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE STEPWISE REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 79960556004     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.11.002     Document Type: Article

References (24)

1. A. Ortiz, F.N. Ziyadeh, and E.G. Neilson Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys J Investig Med 45 1997 50 56 (Pubitemid 127453337)
2. D. Kumar, S. Robertson, and K.D. Burns Evidence of apoptosis in human diabetic kidney Mol Cell Biochem 259 2004 67 70 (Pubitemid 38519217)
3. C. Lorz, A. Benito-Martin, and A. Boucherot The death ligand TRAIL in diabetic nephropathy J Am Soc Nephrol 19 2008 904 914
4. S.T. Knudsen, C.H. Foss, and P.L. Poulsen Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications Eur J Endocrinol 149 2003 39 42 (Pubitemid 36874202)
5. A. Avignon, A. Sultan, and C. Piot Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients Diabetes Care 30 2007 2934 2939 (Pubitemid 350083147)
6. H.M. Terekeci, M.G. Senol, and C. Top Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy Exp Clin Endocrinol Diabetes 117 2009 119 123
7. I. Nabipour, M. Kalantarhormozi, and B. Larijani Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women Metabolism 59 2010 742 747
8. G.D. Xiang, J.H. Pu, and L.S. Zhao Association between plasma osteoprotegerin concentrations and urinary albumin excretion in type 2 diabetes Diabet Med 26 2009 397 403
9. E.P. O'Sullivan, D.T. Ashley, and C. Davenport Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes Diabetes Metab Res Rev 26 2010 496 502
10. N. Bucay, I. Sarosi, and C.R. Dunstan Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1998 1260 1268 (Pubitemid 28213402)
11. B.J. Bennett, M. Scatena, and E.A. Kirk Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice Arterioscler Thromb Vasc Biol 26 2006 2117 2124 (Pubitemid 44253797)
12. D. Siepi, S. Marchesi, and G. Vaudo Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin Metabolism 57 2008 321 325 (Pubitemid 351178720)
13. S. Wang The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway Oncogene 27 2008 6207 6215
14. P. Secchiero, A. Gonelli, and E. Carnevale TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways Circulation 107 2003 2250 2256 (Pubitemid 36547221)
15. G. Zauli, A. Pandolfi, and A. Gonelli Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells Circ Res 92 2003 732 740 (Pubitemid 36457637)
16. Y. Michowitz, E. Goldstein, and A. Roth The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis J Am Coll Cardiol 45 2005 1018 1024 (Pubitemid 40432432)
17. P. Secchiero, F. Corallini, and C. Ceconi Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction PLoS ONE 4 2009 e4442
18. G. Zauli, B. Toffoli, and M.G. di Iasio Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes Diabetes 59 2010 1261 1265
19. G. Zauli, and P. Secchiero The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology Cytokine Growth Factor Rev 17 2006 245 257 (Pubitemid 44038614)
20. J.Y. Shin, Y.G. Shin, and C.H. Chung Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes Diabetes Care 29 2006 1664 1666
21. N. Galal, W. El Beialy, and Y. Deyama Effect of estrogen on bone resorption and inflammation in the temporomandibular joint cellular elements Int J Mol Med 21 2008 785 790
22. O. Shaker, A. El-Shehaby, and M. Nabih Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease Angiology 61 2010 756 762
23. P. Secchiero, F. Corallini, and A.P. Beltrami An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction Atherosclerosis 210 2010 274 277
24. B. Toffoli, S. Bernardi, and R. Candido Osteoprotegerin injection induces morphological and functional alterations in mouse pancreatic islets Mol Cell Endocrinol 331 2011 136 142